MITOXANTRONE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mitoxantrone Hydrochloride, and when can generic versions of Mitoxantrone Hydrochloride launch?
Mitoxantrone Hydrochloride is a drug marketed by Fresenius Kabi Oncol, Fresenius Kabi Usa, Hikma, Hospira, Meitheal, and Rising. and is included in seven NDAs.
The generic ingredient in MITOXANTRONE HYDROCHLORIDE is mitoxantrone hydrochloride. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mitoxantrone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mitoxantrone Hydrochloride
A generic version of MITOXANTRONE HYDROCHLORIDE was approved as mitoxantrone hydrochloride by FRESENIUS KABI USA on April 11th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MITOXANTRONE HYDROCHLORIDE?
- What are the global sales for MITOXANTRONE HYDROCHLORIDE?
- What is Average Wholesale Price for MITOXANTRONE HYDROCHLORIDE?
Summary for MITOXANTRONE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 110 |
Clinical Trials: | 380 |
Patent Applications: | 3,228 |
DailyMed Link: | MITOXANTRONE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MITOXANTRONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Acute Leukemia French Association | Phase 2 |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
CSPC Ouyi Pharmaceutical Co., Ltd. | N/A |
Pharmacology for MITOXANTRONE HYDROCHLORIDE
Drug Class | Topoisomerase Inhibitor |
Mechanism of Action | Topoisomerase Inhibitors |